Kohmann Bosshard Financial Services LLC Reduces Position in Abbott Laboratories (NYSE:ABT)

Kohmann Bosshard Financial Services LLC decreased its stake in shares of Abbott Laboratories (NYSE:ABT) by 24.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,890 shares of the healthcare product maker’s stock after selling 600 shares during the period. Kohmann Bosshard Financial Services LLC’s holdings in Abbott Laboratories were worth $214,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in ABT. Principal Securities Inc. boosted its holdings in shares of Abbott Laboratories by 13.9% during the third quarter. Principal Securities Inc. now owns 32,370 shares of the healthcare product maker’s stock worth $3,691,000 after purchasing an additional 3,952 shares during the last quarter. Americana Partners LLC boosted its holdings in shares of Abbott Laboratories by 55.7% during the third quarter. Americana Partners LLC now owns 13,661 shares of the healthcare product maker’s stock worth $1,557,000 after purchasing an additional 4,887 shares during the last quarter. Roanoke Asset Management Corp NY boosted its holdings in shares of Abbott Laboratories by 4.3% during the third quarter. Roanoke Asset Management Corp NY now owns 53,108 shares of the healthcare product maker’s stock worth $6,055,000 after purchasing an additional 2,197 shares during the last quarter. Lowe Brockenbrough & Co. Inc. boosted its holdings in shares of Abbott Laboratories by 3.8% during the third quarter. Lowe Brockenbrough & Co. Inc. now owns 43,614 shares of the healthcare product maker’s stock worth $4,972,000 after purchasing an additional 1,616 shares during the last quarter. Finally, Weatherly Asset Management L. P. boosted its holdings in shares of Abbott Laboratories by 0.5% during the third quarter. Weatherly Asset Management L. P. now owns 24,315 shares of the healthcare product maker’s stock worth $2,772,000 after purchasing an additional 130 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 1.6 %

NYSE:ABT opened at $137.99 on Friday. The business’s 50-day moving average is $123.08 and its two-hundred day moving average is $117.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $138.37. The firm has a market capitalization of $239.32 billion, a PE ratio of 18.04, a price-to-earnings-growth ratio of 2.52 and a beta of 0.75.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.97 billion for the quarter, compared to analyst estimates of $11.03 billion. During the same period in the previous year, the company earned $1.19 earnings per share. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. Research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.71%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories’s payout ratio is 30.85%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ABT shares. Barclays reiterated an “overweight” rating and issued a $158.00 target price (up previously from $149.00) on shares of Abbott Laboratories in a report on Monday, January 27th. Evercore ISI lifted their target price on Abbott Laboratories to $136.00 and gave the company a “buy” rating in a report on Thursday, January 2nd. Royal Bank of Canada reiterated an “outperform” rating and issued a $135.00 target price on shares of Abbott Laboratories in a report on Tuesday, January 21st. Argus upgraded Abbott Laboratories to a “strong-buy” rating in a report on Tuesday, January 28th. Finally, StockNews.com cut Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Four investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $133.06.

Insider Transactions at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $128.50, for a total value of $3,054,573.50. Following the completion of the sale, the executive vice president now directly owns 125,697 shares of the company’s stock, valued at $16,152,064.50. The trade was a 15.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.10% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.